

[Midazolam](#)

Essential medicine status

Section:

[1. Anaesthetics, preoperative medicines and medical gases 1.3. Preoperative medication and sedation for short-term procedures](#)

ATC codes: [N05CD08](#)

EMLc

Indication

Sedative-hypnotic and anxiolytic drugs ICD11 code: [XM881358505](#)

INN

Midazolam

Medicine type

Chemical agent

List type

Core

Formulations

Parenteral > General injections > IV: 1 mg per mL in 5 vial ; 5 mg per mL in 1 mL vial ; 5 mg per mL in 3 mL vial

Oral > Liquid: 2 mg per mL (EMLc)

Oral > Solid > dosage form: 15 mg (EML) ; 7.5 mg (EML)

EML status history

First added in 2011 ([TRS 965](#))

Changed in 2021 ([TRS 1035](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

Medicines within the same pharmacological class can be used

Therapeutic alternatives limitations

Therapeutic alternatives to be reviewed (2023)

Therapeutic alternatives limitations for EMLc

Therapeutic alternatives to be reviewed (2023)

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Midazolam](#)

DrugBank

[Midazolam](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - to delete midazolam tablets 7.5 mg and 15 mg from the EMLc. - to modify the formulation descriptions of midazolam injection to better describe the available dosage forms.